Posts

Showing posts with the label HER2-Positive Gastric Cancer Emerging Therapy

HER2-Positive Gastric Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

HER2-Positive Gastric Cancer Emerging Therapy and TPP Insights Thelansis’s “HER2-Positive Gastric Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product P...

HER2-Positive Gastric Cancer – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034

HER2-Positive Gastric Cancer Emerging Therapy Thelansis’s “HER2-Positive Gastric Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report – 2024 To 2034″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . HER2-Positive Gastric Cancer Overview HER2-positive gastric cancer refers to a specific subtype of stomach cancer that is characterized by overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a gene that plays a role in normal cell growth, but when overexpressed in cancer cells, it can promote the growth and spread of cancer. In gastric cancer, HER2 overexpression is found in a subset of tumors, estimated to be around 10-20% of cases. The overexpression of HER2 is typically assessed through immunohistochemistry (IHC) or fluorescence in situ h...